Nesrin Karabul

Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document

Marieke Biegstraaten, Reynir Arngrı́msson, Frédéric Barbey et al. · Orphanet Journal of Rare Diseases · 2015 · 345 citations · Full text

Life Sciences, Internal Medicine, Pharmacotherapy +13

A cross-sectional single-centre study on the spectrum of Pompe disease, German patients: molecular analysis of the GAA gene, manifestation and genotype-phenotype correlations

Andreas Herzog, Ralf Hartung, Arnold Reuser et al. · Orphanet Journal of Rare Diseases · 2012 · 89 citations · Full text

Life Sciences, Genetics, Molecular Genetics +15

Treatment of Fabry's Disease With Migalastat: Outcome From a Prospective Observational Multicenter Study (FAMOUS)

Malte Lenders, Peter Nordbeck, Christine Kurschat et al. · Clinical Pharmacology & Therapeutics · 2020 · 68 citations

Life Sciences, Pharmacology, Pharmacotherapy +17

Outcome of Patients with Classical Infantile Pompe Disease Receiving Enzyme Replacement Therapy in Germany

Andreas Hahn, Susanne Praetorius, Nesrin Karabul et al. · JIMD Reports · 2014 · 61 citations

Medicine, Cardiology, Pediatrics +8

Treatment of Fabry Disease management with migalastat—outcome from a prospective 24 months observational multicenter study (FAMOUS)

Malte Lenders, Peter Nordbeck, Christine Kurschat et al. · European Heart Journal - Cardiovascular Pharmacotherapy · 2021 · 61 citations

Life Sciences, Cardiology, Pharmacotherapy +16